{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:30:55Z","timestamp":1789133455620,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1U01HL163983"],"award-info":[{"award-number":["1U01HL163983"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01FD007829"],"award-info":[{"award-number":["5R01FD007829"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1K99DK134844"],"award-info":[{"award-number":["1K99DK134844"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002803","name":"Diamond Blackfan Anemia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St. Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030442","name":"Anna Fuller Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcyt.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:18:11Z","timestamp":1725646691000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee"],"prefix":"10.1016","volume":"27","author":[{"given":"Joseph H.","family":"Oved","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-921X","authenticated-orcid":false,"given":"Athena","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Prockop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmem","family":"Bonfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0408-8455","authenticated-orcid":false,"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8410-8662","authenticated-orcid":false,"given":"Madhavi","family":"Lakkaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6078-4028","authenticated-orcid":false,"given":"Alan","family":"Bidgoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6549","authenticated-orcid":false,"given":"Senthil Velan","family":"Bhoopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-0442","authenticated-orcid":false,"given":"Sandeep","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2019-0887","authenticated-orcid":false,"given":"Allistair","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.09.001_bib0001","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0002","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0003","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ajh.27293","article-title":"HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: a retrospective analysis on behalf of EBMT severe aplastic anemia and pediatric diseases working parties","volume":"99","author":"Giardino","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0004","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/petr.12109","article-title":"Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children\u2019s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry","volume":"17","author":"Mitchell","year":"2013","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0006","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0007","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809958","article-title":"Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives","volume":"11","author":"Naldini","year":"2019","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bognar","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0011","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0012","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2016.103","article-title":"The role of conditioning in hematopoietic stem-cell gene therapy","volume":"27","author":"Bernardo","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ni0610-457","article-title":"20 years of gene therapy for SCID","volume":"11","author":"Fischer","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0014","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/sj.mt.6300297","article-title":"New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy","volume":"15","author":"Pike-Overzet","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41434-021-00261-x","article-title":"The transformative potential of HSC gene therapy as a genetic medicine","volume":"30","author":"Sagoo","year":"2023","journal-title":"Gene Therapy"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0017","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2020","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0019","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fgeed.2021.618378","article-title":"Gene editing of hematopoietic stem cells: hopes and hurdles toward clinical translation","volume":"3","author":"Ferrari","year":"2021","journal-title":"Front Genome Editing"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent beta-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0021","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0022","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/eji.200838383","article-title":"Space-time considerations for hematopoietic stem cell transplantation","volume":"38","author":"Bhattacharya","year":"2008","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0023","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation.V2012.1.237.3798315","article-title":"Do different conditioning regimens really make a difference?","volume":"2012","author":"Blaise","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0026","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0027","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0028","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/s41591-019-0550-z","article-title":"Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia","volume":"25","author":"Rio","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","article-title":"Gene therapy using haematopoietic stem and progenitor cells","volume":"22","author":"Ferrari","year":"2021","journal-title":"Nature Rev Genet"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0030","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ymthe.2020.11.020","article-title":"Update on clinical ex vivo hematopoietic stem cell gene therapy for inherited monogenic diseases","volume":"29","author":"Tucci","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0031","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtm.2019.10.010","article-title":"Immunoresponse to gene-modified hematopoietic stem cells","volume":"16","author":"Drysdale","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0032","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0033","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0034","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2010.031013","article-title":"Quantitatively different red cell\/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease","volume":"96","author":"Marco","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0036","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3324\/haematol.2010.035576","article-title":"In mixed hematopoietic chimerism, the donor red cells win","volume":"96","author":"Matthew","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0037","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0038","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0039","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ajh.25909","article-title":"Gene therapies for transfusion dependent \u03b2-thalassemia: current status and critical criteria for success","volume":"95","author":"Soni","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0040","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0041","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0042","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2019-126046","article-title":"Northstar-2: updated safety and efficacy analysis of lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and non-\u03b20\/\u03b20 genotypes","volume":"134","author":"Thompson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0043","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2019-128482","article-title":"Northstar-3: interim results from a phase 3 study evaluating lentiglobin gene therapy in patients with transfusion-dependent \u03b2-thalassemia and either a \u03b20 or IVS-I-110 mutation at both alleles of the HBB gene","volume":"134","author":"Lal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0044","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.bbmt.2019.12.588","article-title":"Interim results from the phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) studies of betibeglogene autotemcel gene therapy (LentiGlobin) for the treatment of transfusion-dependent \u03b2-thalassemia","volume":"26","author":"Schneiderman","year":"2020","journal-title":"Biol Blood Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0045","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non\u2013\u03b20\/\u03b20 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0046","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-139575","article-title":"Safety and efficacy of CTX001 in patients with transfusion-dependent \u03b2-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells","volume":"136","author":"Frangoul","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0047","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0048","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2019-125743","article-title":"Preliminary results of a phase 1\/2 clinical study of zinc finger nuclease-mediated editing of BCL11A in autologous hematopoietic stem cells for transfusion-dependent beta thalassemia","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0049","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2021-151650","article-title":"Preliminary safety and efficacy results from Precizn-1: an ongoing phase 1\/2 study on zinc finger nuclease-modified autologous CD34+ HSPCs for sickle cell disease (SCD)","volume":"138","author":"Alavi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41591-021-01554-9","article-title":"Lentiviral globin gene therapy with reduced-intensity conditioning in adults with beta-thalassemia: a phase 1 trial","volume":"28","author":"Boulad","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0051","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1749-6632.2010.05597.x","article-title":"Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia","volume":"1202","author":"Sadelain","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0052","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood-2021-147469","article-title":"Safety and efficacy of Aru-1801 in patients with sickle cell disease: early results from the phase 1\/2 momentum study of a modified gamma globin gene therapy and reduced intensity conditioning","volume":"138","author":"Grimley","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0053","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.ymthe.2021.03.010","article-title":"A pause in gene therapy: reflecting on the unique challenges of sickle cell disease","volume":"29","author":"Leonard","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0054","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0056","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156060","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"132","author":"Liggett","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158251","article-title":"The hematopoietic saga of clonality in sickle cell disease","volume":"132","author":"Stonestrom","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0058","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Spencer Chapman","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0059","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021011488","article-title":"Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither","volume":"138","author":"Jones","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0060","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0061","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa2106596","article-title":"Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome","volume":"385","author":"Gentner","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0062","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJMoa1700554","article-title":"Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy","volume":"377","author":"Eichler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0063","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0140-6736(21)02017-1","article-title":"Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1\/2 trial and expanded access","volume":"399","author":"Fumagalli","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0064","article-title":"Molecular, cellular and clinical implications of lentiviral-mediated gene therapy in patients with Fanconi anemia","volume":"35","author":"Rio","year":"2024","journal-title":"Human Gene Therapy"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0065","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0066","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0067","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0068","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0069","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41591-021-01641-x","article-title":"Long-term safety and efficacy of lentiviral hematopoietic stem\/progenitor cell gene therapy for Wiskott-Aldrich syndrome","volume":"28","author":"Magnani","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0071","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/blood-2018-06-853879","article-title":"Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice","volume":"133","author":"Kwon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0072","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2021-153074","article-title":"JSP191 as a single-agent conditioning regimen results in successful engraftment, donor myeloid chimerism, and production of donor derived na\u00efve lymphocytes in patients with severe combined immunodeficiency (SCID)","volume":"138","author":"Agarwal","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0073","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nature Commun"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0074","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.2023023549","article-title":"Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate conditioned Fanconi anemia mice","volume":"143","author":"Saha","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0075","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/bloodadvances.2021006700","article-title":"Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia","volume":"6","author":"Dekker","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.09.001_bib0076","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/bloodadvances.2021005564","article-title":"Tisagenlecleucel outcomes in relapsed\/refractory extramedullary ALL: a pediatric real world CAR consortium report","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:11:03Z","timestamp":1762546263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924008387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1465324924008387"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.09.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}